Lv1
30 积分 2024-11-17 加入
Aligning patient‐reported priorities in immune thrombocytopenia with clinical and regulatory advances: Insights from rilzabrutinib
1天前
已完结
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study
1天前
已关闭
Multiple sclerosis updates and the safety and efficacy of Bruton tyrosine kinase inhibitors in it: A systematic review
11天前
已完结
Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database
2个月前
已完结
Mitochondrial ROS-dependent CD4+PD-1+T cells are pathological expansion in patients with primary immune thrombocytopenia
2个月前
已完结
Immune thrombocytopenia (ITP) - could it be part of autoimmune/inflammatory syndrome induced by adjuvants (ASIA)?
2个月前
已完结
Real-World Outcomes with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective Study
2个月前
已完结
Phase Ib study with expansion of ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory CNS lymphoma
2个月前
已完结
皖公网安备34019202002308
